SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001824293-22-000046
Filing Date
2022-06-06
Accepted
2022-06-06 17:12:26
Documents
6
Period of Report
2022-07-13

Document Format Files

Seq Description Document Type Size
1 DEF 14A definitiveproxyspecialshme.htm DEF 14A 460908
2 GRAPHIC dpivallonpharmaceuticalsin.jpg GRAPHIC 190590
3 GRAPHIC dpivallonpharmaceuticalsina.jpg GRAPHIC 406317
4 GRAPHIC image_0.jpg GRAPHIC 34071
5 GRAPHIC image_1.jpg GRAPHIC 16454
6 GRAPHIC image_2.jpg GRAPHIC 3154
  Complete submission text file 0001824293-22-000046.txt   1357550
Mailing Address TWO LOGAN SQUARE 100 N. 18TH STREET, SUITE 300 PHILADELPHIA PA 19103
Business Address TWO LOGAN SQUARE 100 N. 18TH STREET, SUITE 300 PHILADELPHIA PA 19103 (267) 207-3606
Vallon Pharmaceuticals, Inc. (Filer) CIK: 0001824293 (see all company filings)

IRS No.: 824369909 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40034 | Film No.: 22998879
SIC: 2834 Pharmaceutical Preparations